Kit For The Preparation Of Technetium Tc 99m Mebrofenin label

Kit For The Preparation Of Technetium Tc 99m Mebrofenin

Kit For The Preparation Of Technetium Tc 99m Mebrofenin Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

The theoretical possibility of allergic reactions should be considered in patients who receive multiple doses.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Technetium Tc 99m Mebrofenin is indicated as a hepatobiliary imaging agent.

History

There is currently no drug history available for this drug.

Other Information

Each multidose reaction vial contains a nonradioactive, sterile, nonpyrogenic mixture of 45 mg mebrofenin, 0.54 mg (minimum) stannous fluoride dihydrate, SnF2•2H2O and 1.03 mg total tin, maximum (as stannous fluoride dihydrate, SnF2•2H2O), not more than 5.2 mg methylparaben, and 0.58 mg propylparaben. The pH is adjusted with sodium hydroxide or hydrochloric acid prior to lyophilization. The contents of the vial are lyophilized and sealed under nitrogen at the time of manufacture.

The pH of the reconstituted product is 4.2 to 5.7.

The structure of mebrofenin (2,2′-[[2-[(3-Bromo-2,4,6-trimethylphenyl)-amino]-2-oxoethyl]imino] bisacetic acid) is shown below:

Structure of Mebrofenin

Molecular Weight = 387.23

When sterile, pyrogen-free sodium pertechnetate Tc 99m injection is added to the vial, the diagnostic agent Technetium Tc 99m Mebrofenin is formed for administration by intravenous injection.

PHYSICAL CHARACTERISTICS

Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours.1 The principal photon that is useful for detection and imaging studies is listed in Table 1.

TABLE 1

Principal Radiation Emission Data

Radiation

Mean % per Disintegration

Mean Energy (keV)

Gamma-2

89.07

140.5

1Kocher, David C., “Radioactive Decay Data Tables”, DOE/TIC-11026, (1981) p. 108.

External Radiation

The specific gamma ray constant for Tc 99m is 0.78 R/hour-millicurie at 1 cm. The first half value layer is 0.017 cm of lead (Pb). A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 2. To facilitate control of the radiation exposure from millicurie amounts of this radionuclide, the use of a 0.25 cm thickness of Pb will attenuate the radiation emitted by a factor of about 1,000.

TABLE 2

Radiation Attenuation by Lead Shielding

Shield Thickness (Pb) cm

Coefficient of Attenuation

0.017

0.5

0.08

10-1

0.16

10-2

0.25

10-3

0.33

10-4

To correct for physical decay of technetium Tc 99m, the fractions that remain at selected intervals after the time of calibration are shown in Table 3.

TABLE 3

Physical Decay Chart: Tc 99m half-life 6.02 hours

Hours

Fraction Remaining

Hours

Fraction Remaining

0*

1.000

7

0.447

1

0.891

8

0.398

2

0.794

9

0.355

3

0.708

10

0.316

4

0.631

11

0.282

5

0.562

12

0.251

6

0.501

18

0.126

*Calibration time

Kit For The Preparation Of Technetium Tc 99m Mebrofenin Manufacturers

  • Kit For The Preparation Of Technetium Tc 99m Mebrofenin | Pharmalucence, Inc.
    No Recall

    Kit For The Preparation Of Technetium Tc 99m Mebrofenin | Pharmalucence, Inc.

    Kit For The Preparation Of Technetium Tc 99m Mebrofenin | Pharmalucence, Inc.

    The suggested intravenous dose range of Technetium Tc 99m Mebrofenin in the average patient (70 kg) is:

      Nonjaundiced patient: 74 - 185 MBq (2-5 mCi)   Patient with serum bilirubin   level greater than 1.5 mg/dL: 111-370 MBq (3-10 mCi)

    The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

    The patient should be in a fasting state, 4 hours is preferable. False positives (non-visualization) may result if the gallbladder has been emptied by ingestion of food.

    An interval of at least 24 hours should be allowed before repeat examination.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

     

    RADIATION DOSIMETRY

    The estimated absorbed radiation doses1,2 to organs and tissues of an average subject (70 kg) from an intravenous injection of 370 MBq (10 millicuries) of Technetium Tc 99m Mebrofenin are shown in Table 4.

    TABLE 4

    Estimated Absorbed Radiation Doses†

    Normal Subjects*

    Severely Jaundiced

    Patients**

    Tissue

    mGy/

    370 MBq

    rads/

    10 mCi

    mGy/

    370 MBq

    rads/

    10 mCi

    Total Body

    2.0

    0.2

    1.7

    0.17

    Liver

    4.7

    0.47

    8.1

    0.81

    Gallbladder Wall

    13.7

    1.37

    12.5

    1.25

    Small Intestine

    29.9

    2.99

    16.0

    1.60

    Upper Large

    Intestine Wall

    47.4

    4.74

    24.8

    2.48

    Lower Large

    Intestine Wall

    36.4

    3.64

    19.7

    1.97

    Kidney

    2.2

    0.22

    1.9

    0.19

    Urinary Bladder Wall

    2.9

    0.29

    24.2

    2.42

    Ovaries

    10.1

    1.01

    6.4

    0.64

    Testes

    0.5

    0.05

    1.1

    0.11

    Red Marrow

    3.4

    0.34

    2.5

    0.25

    †Method of Calculation:

    (1) Loberg, M.D., Buddemeyer, E.V.: Application of pharmacokinetic modeling to the radiation dosimetry of hepatobiliary agents. In Third International Radiopharmaceutical Dosimetry Symposium, FDA No. 81-8166, U.S. Department of Health and Human Services, Public Health Service, FDA, Bureau of Radiological Health, Rockville, MD, (1981) pp. 318-332.

    (2) Values for S: "S", Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs, MIRD Pamphlet No. 11 (1975).

    * Bilirubin <1.5 mg/dL

    Calculations assume that 98% of the injected activity is taken up by the liver; activity not removed in the urine in 24 hours is excreted in the intestines and no enterohepatic circulation of activity.

    ** Bilirubin >10 mg/dL (mean 21.8 mg/dL)

    Calculations assume that 66% of the injected activity is taken up by the liver; activity not removed in the urine in 24 hours is excreted in the intestines and no enterohepatic circulation of activity.